Abstract: The present invention provides a polymerizable compound represented by the following formula (I), a polymerizable composition that includes the polymerizable compound and an initiator, a polymer obtained by polymerizing the polymerizable compound or the polymerizable composition, and an optically anisotropic article that includes the polymer. The polymerizable compound, polymerizable composition, and polymer have a practical low melting point, exhibit an excellent solubility in a general-purpose solvent, can be produced at low cost, and may produce an optical film that achieves uniform conversion of polarized light over a wide wavelength band, and an optically anisotropic article.

Abstract: The present description relates to compounds of Formula I (A+ X?), a diastereoisomer, an enantiomer, or a mixture thereof, pharmaceutical composition comprising same and uses thereof for gastrointestinal endoscopic and medical imaging applications, and for the treatment of visceral pain: Where R1 and R2 are as defined herein

Abstract: A liquid crystal composition comprising a compound represented by the following formula has sufficient solubility and a wide usable concentration range, and exhibits excellent haze-lowering performance. B1 represents an n-valent chain linking group, L1 and L2 represent a single bond, —O—, —S—, —CO—, —COO—, —OCO—, etc, A1 represents a divalent aromatic hydrocarbon group or a divalent heterocyclic group, A2 represents an aromatic hydrocarbon group, Sp1 represents a single bond, or an alkylene group, Hb1 represents a fluorine-substituted alkyl group, n represents 2 to 6, m represents 0 to 2, and l represents 2 or 3.

Abstract: Synthetic polyphenolic compounds of formula (I), their modes of synthesis, and pharmaceutical compositions thereof are provided herein. Use of the compounds and compositions described herein for treating cancer and for treating metabolic disorders is also provided.

Abstract: Compounds that bind the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, methods of their therapeutic and/or prophylactic use, and methods of their use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor are provided. Certain compounds may have activity as modulators or potentiators with respect to glucagon receptor, GIP receptor, GLP-1 and GLP-2 receptors, and PTH receptor on their own or in the presence of receptor ligands such as GIP (1-42), PTH (1-34), Glucagon (1-29), GLP-2 (1-33), GLP-1 (7-36), GLP-1 (9-36), oxyntomodulin and exendin variants.

Abstract: Esters of O-substituted hydroxy carboxylic acids are provided having Formula 1, or 2, or both Formulas 1 and 2: wherein R and R1 are independently selected from the group consisting of substituted and unsubstituted, branched- and straight-chain, saturated, unsaturated, and polyunsaturated C1-C22 alkyl, substituted and unsubstituted C3-C8 cycloalkyl, substituted and unsubstituted C6-C20 carbocyclic aryl, and substituted and unsubstituted C4-C20 heterocyclic; wherein the heteroatoms are selected from sulfur, nitrogen, and oxygen; and wherein n is 1-6. Process of producing esters of O-substituted hydroxy carboxylic acids are also provided.

Abstract: The present invention provides a polymerizable compound represented by the following formula (I), a polymerizable composition that includes the polymerizable compound and an initiator, a polymer obtained by polymerizing the polymerizable compound or the polymerizable composition, and an optically anisotropic article that includes the polymer. The invention makes it possible to provide a polymerizable compound, a polymerizable composition, and a polymer that have a practical low melting point, exhibit an excellent solubility in a general-purpose solvent, can be produced at low cost, and may produce an optical film that achieves uniform conversion of polarized light over a wide wavelength band, and an optically anisotropic article.

Abstract: The present invention provides a compound of which active |form| is represented by a formula (A). and which can be injected into a joint cavity which is an affected part of disorders and can be accumulated in the joint cavity to exert the pharmacological effect thereof in a sustained manner, for the purpose of ameliorating cartilage disorders without developing any side effect. A compound according to the present invention, which is represented by a formula (I): (wherein all of symbols are as defined in the description), is a compound that can achieve the above-mentioned purpose. This compound does not exhibit any side effect on the cardiovascular system even when the compound is administered in an effective amount for exhibiting a cartilage regeneration activity, and is therefore extremely useful as a safe and effective preventive and/or therapeutic agent for cartilage disorders.

Abstract: A compound represented by the following formula (1) has sufficient solubility, a wide usable concentration range, and excellent haze-lowering performance. In the formula, L1 to L6 represent a single bond, —O—, —CO—, —COO—, etc; Sp1 to Sp4 represent a single bond or alkylene of 1 to 10 carbon atoms; A1 and A2 represent trivalent or tetravalent aromatic hydrocarbon or heterocyclic; T represents the following formulae, etc; Hb represent perfluoroalkyl of 2 to 30 carbon atoms; m and n are 2 or 3; and o and p are an integer of 0 or more.

Abstract: A liquid crystal composition comprising a chiral dopant compound represented by the following structure (Structure 1): wherein: R1 and R2 are independently hydrogen, —(C?O)R9, —(C?O)R10, alkyl, aryl, alkaryl, alkenyl, cycloalkyl, alkoxyaryl, or heterocyclic all either substituted or unsubstituted, or combine to form a carbocyclic or heterocyclic ring; R3 is hydrogen, halogen, cyano, alkoxy, NHCOR9, NHSO2R9, COOR9, OCOR9, aryl, alkyl, alkenyl, cycloalkyl, or heterocyclic all either substituted or unsubstituted; R4 is hydrogen, alkyl, aryl, alkenyl, cycloalkyl, or heterocyclic all either substituted or unsubstituted; R5, R6, R7, and R8 are independently hydrogen, halogen, cyano, alkoxy, NHCOR9, NHSO2R9, COOR9, OCOR9, aryl, alkyl, alkenyl, cycloalkyl, alkoxyaryl or heterocyclic all either substituted or unsubstituted, or combine with each other, or R5 can combine with R4 to form a carbocyclic or heterocyclic ring; R9 and R10 are independently alkyl, alkoxy, aryl, naphthyl, styryl, alkenyl, cycloalkyl, alko

Abstract: The present invention relates to the use of compounds which are capable of attenuating skin irritation when they are applied to the skin. Skin irritation can be caused, inter alia, by ingredients of cosmetic or pharmaceutical compositions and/or environmental irritants. In particular, the present invention relates to compounds having the property of antagonizing the activation of the transient receptor potential (TRP) ankyrin 1 (TRPA1) ion channel and the use of said compounds as soothing agents. Such compounds can be used in many fields, particularly in personal-care products, cosmetics, textile and packaging products, pharmaceutical compositions, medical devices, and foodstuffs. The present invention further relates to products and/or pharmaceutical compositions containing said compounds. The present invention also relates to the use of the compounds described herein for the modulation of the taste of a food product.

Abstract: A liquid crystal composition comprising a chiral dopant compound represented by the following structure (Structure 1): wherein: R1 and R2 are independently hydrogen, —(C?O)R9, —(C?O)R10, alkyl, aryl, alkaryl, alkenyl, cycloalkyl, alkoxyaryl, or heterocyclic all either substituted or unsubstituted, or combine to form a carbocyclic or heterocyclic ring; and R3-R9 are as described in the disclosure. Also featured are liquid crystal compositions comprising a chiral dopant compound represented by any of Structure 2-4 as described in the disclosure.

Abstract: The invention provides a compound of the formula: wherein Ar is selected from the group consisting of aryl, monosubstituted aryl and polysubstituted aryl, heteroaryl, monosubstituted heteroaryl and polysubstituted heteroaryl; Ar? is selected from the group consisting of aryl, monosubstituted aryl and polysubstituted aryl, heteroaryl, monosubstituted heteroaryl and polysubstituted heteroaryl; R is an alkylene radical having 2-20 carbon atoms; and n=1-20. The compounds of the invention are used with polymer resins to enhance their gas barrier properties.

Abstract: To provide a polymerizable liquid crystal composition showing good coating properties even when a support substrate has a low solvent resistance, and having uniform alignment properties. A polymerizable liquid crystal composition is prepared by containing as components an acrylate polymerizable liquid crystal compound, a compound represented by formula (3), and a non-liquid crystalline compound having an acryloyl group or a methacryloyl group as a reactive moiety, and having a functional group including a hydroxyl group as a reactive dilution solvent in one molecule. When the polymerizable liquid crystal composition is applied onto the support substrate, dried and irradiated with light, the polymerizable liquid crystal composition showing good coating properties even when the support substrate has the low solvent resistance, and having the uniform alignment properties can be obtained.

Abstract: A photoacid generator represented by the following formula (1), a method for producing the photoacid generator, and a resist composition containing the photoacid generator are provided. wherein in the formula (1), Y1, Y2, X, R1, R2, n1, n2 and A+ have the same meanings as defined in the detailed description of the invention. The photoacid generator can maintain an appropriate contact angle at the time of ArF liquid immersion lithography, can reduce defects occurring during liquid immersion lithography, and has excellent solubility in resist solvents and excellent compatibility with resins. Furthermore, the photoacid generator can be produced by an efficient and simple method using an epoxy compound that is industrially easily available.

Abstract: The invention relates to compounds of general formula I, (I), wherein R is wherein R is aryl substituted by R3; or R is (C3-Ci3)-cycloalkyl, (C3-Ci3)-cycloalkenyl or (C7-Ci3)-cycloalkynyl optionally substituted by R4; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.

Abstract: An inhibitor of endothelin action or a skin-whitening agent, comprising a compound represented by Formula (1) or a salt thereof as an active ingredient. wherein in Formula (1), R1 represents a formyl group or an alkyl group having 1 to 4 carbon atom(s), and R2 represents a hydrogen atom or an alkyl group having 1 to 4 carbon atom(s).

Abstract: A novel polymerizable monomer is provided. A novel liquid crystal composition which can be used in a variety of liquid crystal devices is provided using the polymerizable monomer. The use of the novel liquid crystal composition makes it possible to reduce driving voltage of a liquid crystal element and to reduce power consumption of a liquid crystal display device. A polymerizable monomer represented by General Formula (G1) is provided. A liquid crystal composition which includes a polymerizable monomer represented by General Formula (H1), a nematic liquid crystal, and a chiral material is also provided. In General Formulae (G1) and (H1), n and m are individually an integer from 1 to 20, and R1 and R2 individually represent hydrogen or a methyl group. In General Formulae (G1), k is 2 or 3.

Abstract: A polymerizable liquid crystal compound shown by the following formula, a polymerizable liquid crystal composition that includes the polymerizable liquid crystal compound and a chiral compound polymerizable with the polymerizable liquid crystal compound, a liquid crystalline polymer obtained by polymerizing the polymerizable liquid crystal compound or the polymerizable liquid crystal composition, and an optically anisotropic article that includes the liquid crystalline polymer, are disclosed.

Abstract: A liquid crystal compound of Formula (I) is provided. In Formula (I), A is benzene, naphthalene, pyridine, furan, thiophene or a single bond, D is benzene, naphthalene, pyridine, furan, thiophene or a single bond, R1 and R2 are C1-10 alkyl, C1-10 alkoxy, fluoro or trifluoro methyl, E is benzene, naphthalene, pyridine, furan, thiophene or a single bond, W is —CO—O—, —O—CO—, —O—, —CH2—CH2—, —CH?CH—, —CH2—O— or a single bond, Z is benzene, naphthalene, pyridine, furan, thiophene or a single bond, Y is hydrogen, methyl, ethyl or propyl, m is 0, 1 or 2, p is 0, 1 or 2, r is 0, 1 or 2, q is 0, 1 or 2, and n is 0, 1, 2 or 3. The invention also provides a liquid crystal display and photochromic material including the compound.

Abstract: The present application provides novel compounds and methods for preparing and using these compounds. These compounds are useful in treating pain, itch, overactive bladder and/or interstitial cystitis in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) and a TRPV1 receptor activator. In one embodiment, the TRPV1 receptor activator is lidocaine.

Abstract: A process for making bis(aryloxyalkyl)terephthalates useful as antiplasticizers for thermoplastic polyesters is disclosed. Dimethyl terephthalate is reacted with an excess of an aryloxyalkanol in the presence of a condensation catalyst to produce an intermediate mixture comprising a bis(aryloxyalkyl)terephthalate, a mono(aryloxyalkyl)terephthalate, and unreacted aryloxyalkanol. This mixture continues to react at reduced pressure while unreacted aryloxyalkanol is removed and the mono-ester content is reduced to less than 1 mole % based on the combined amounts of mono- and bis-esters. Both steps are performed substantially in the absence of oxygen. Additional unreacted aryloxyalkanol is then removed to provide a purified bis(aryloxyalkyl)terephthalate having an overall purity of at least 98 mole % and a yellowness index less than 10.

Abstract: The invention concerns compounds of the formula: X—(Y)t wherein: X is Formula (X), each Y is the same or different and is Formula (Y) —O—[CH2—CH(OH)—CH2—O—]m—H; or —C(OR5)3; R1, R2, R3, R6, R7, R8, R9, R10 are each, independently, —(CH2CH2O)m—R4, —[CH2CH(OH)CH2O]nH, OR11, —O(CH2)PR13, or —(CH2)R12; each R4 is independently OR5 or OH; R5, R11 and R12 are each, independently, H or C1-C30 alkyl; R13 is —NH3+Cl? or —NHBoc; t is an integer from 2 to 6; m, n, and p are each, independently, an integer from 1 to 12; and each q, r, and s is 0 or 1 and the sum of q+r+s is at least 2.

Abstract: A polymerizable liquid crystal compound represented by formula (I) is disclosed. R0 and R1 represent a hydrogen atom, or a C1-4 alkyl group, provided that at least one of R0 and R1 represent a C1-4 alkyl group; A0, A1, B0 and B1 represent a single bond, or a divalent linking group having a cyclic structure; X0, X1, Y0 and Y1 represent a single bond, —O—, —S—, —OCO—, —COO—, —OCOO—, —NR2CO—, —CONR2—, —OCONR2—, —NR2COO—, —NR2CONR2—, —C?N— or —N?C—; Q0 and Q1 a single bond or a divalent aliphatic group; Z0 and Z1 represent a hydrogen atom, cyano, halogen atom or polymerizable group; and n and m each independently represent an integer of from 0 to 2.

Abstract: The invention relates to novel mesogenic dimeric compounds which are especially suitable for use in birefringent films with negative optical dispersion, to novel liquid crystal (LC) formulations and polymer films comprising them, and to the use of the dimers, formulations and films in optical, electrooptical, electronic, semiconducting or luminescent components or devices.

Abstract: The present invention relates to a novel process for producing polyesteretherols via alkoxylation of polyesterols, and also to the use of the polyesteretherols for producing polyurethanes.

Abstract: A liquid crystal compound having a large refractive index anisotropy, a large dielectric anisotropy, and a low melting point, and a liquid crystal medium having a liquid crystal phase over a wide temperature range, a large refractive index anisotropy, a large dielectric anisotropy, and having an optically isotropic liquid crystal phase, are provided. The present invention is a liquid crystal compound having a chlorobenzene ring, and a liquid crystal medium characterized by containing the liquid crystal compound and a chiral reagent, and exhibiting an optically isotropic liquid crystal phase.

Abstract: The invention provides a compound of the formula: wherein Ar is selected from the group consisting of aryl, monosubstituted aryl and poly-substituted aryl, heteroaryl, monosubstituted heteroaryl and polysubstituted heteroaryl; Ar? is selected from the group consisting of aryl, monosubstituted aryl and polysubstituted aryl, heteroaryl, monosubstituted heteroaryl and polysubstituted heteroaryl; R is an alkylene radical having 2-20 carbon atoms; and n=1-20. The compounds of the invention are used with polymer resins to enhance their gas barrier properties.

Abstract: A trifunctional (meth)acrylate compound of general formula (I) is provided The compound is capable of retaining a liquid crystal phase at or below 30 ° C. Polymerizable compositions containing a compound of formula (I) are also provided.

Abstract: A photosensitive compound whose size is smaller than conventional polymer for photoresist, and which has well-defined (uniform) structure, and a photoresist composition including the same are disclosed. The photosensitive compound represented by the following formula. Also, the present invention provides a photoresist composition comprising 1 to 85 wt % (weight %) of the photosensitive compound; 0.05 to 15 weight parts of a photo-acid generator with respect to 100 weight parts of the photosensitive compound; and 10 to 5000 weight parts of an organic solvent. In the formula, n is 0 or 1, x is 1, 2, 3, 4 or 5, y is 2, 3, 4, 5 or 6, z is 0, 1, 2, 3 or 4, R, R? and R? are independently hydrocarbon group of 1 to 30 carbon atoms, preferably 2 to 20 carbon atoms, and R?? is a hydrogen atom or hydrocarbon group of 1 to 30 carbon atoms, preferably 2 to 20 carbon atoms.

Abstract: A polymerizable liquid crystal compound represented by formula (I) is disclosed. R0 and R1 represent a hydrogen atom, or a C1-4 alkyl group, provided that at least one of R0 and R1 represent a C1-4 alkyl group; A0, A1, B0 and B1 represent a single bond, or a divalent linking group having a cyclic structure; X0, X1, Y0 and Y1 represent a single bond, —O—, —S—, —OCO—, —COO—, —OCOO—, —NR2CO—, —CONR2—, —OCONR2—, —NR2COO—, —NR2CONR2—, —C?N— or —N?C—; Q0 and Q1 a single bond or a divalent aliphatic group; Z0 and Z1 represent a hydrogen atom, cyano, halogen atom or polymerizable group; and n and m each independently represent an integer of from 0 to 2.

Abstract: Disclosed herein is a method for synthesizing terpenoid compounds, as well as compositions comprising terpenoids and methods for their use. In one aspect the process is represented by the scheme wherein G is X is and R1, R2 and R3 independently are selected from H, acyl, lower alkyl and aralkyl; and Y is —O—, —S— or —NH—, and R4 is selected from H, acyl, lower alkyl and aralkyl.

Abstract: The present invention discloses low viscosity aromatic polyester polyols suitable for blending with other polyols or other materials mutually compatible with the polyester polyols to achieve polyurethane and polyisocyanurate products. In particular the present invention discloses polyester polyols comprising the reaction of: A) an aromatic component comprising at 80 mole percent or greater of terephthalic acid; B) polyethylene glycol having a molecular weight from 150 to 1000; and C) a glycol different from the glycol of B); wherein A, B, and C are present in the reaction on a percent weight bases of 20 to 60 weight percent A); 40 to 75 weight percent of B); and 0 to 40 weight percent of C).

Abstract: The present invention relates to a light absorbent for organic anti-reflection coating formation, and an organic anti-reflection film composition containing the same. The light absorbent for organic anti-reflection film formation according to the present invention is a compound of the following formula (1a), a compound of the following formula (1b), a mixture of compounds of the formulas (1a) and (1b): wherein X is selected from the group consisting of a substituted or unsubstituted cyclic group having 1 to 20 carbon atoms, aryl, diaryl ether, diaryl sulfide, diaryl sulfoxide and diaryl ketone; and R1 is a hydrogen atom, a substituted or unsubstituted alkyl group having 1 to 10 carbon atoms, or an aryl group having 1 to 14 carbon atoms.

Abstract: A photosensitive compound has two or more structural units, in a molecule, represented by the following general formula (1): wherein R1 to R8 are selected from the group consisting of a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, an acetoxy group, a phenyl group, a naphthyl group, and an alkyl group in which some or all of the hydrogen atoms are optionally replaced by fluorine atoms; R9 is a hydrogen atom or a hydroxyl group; X is a substituted or unsubstituted phenylene group or a substituted or unsubstituted naphthalene group; and Y is an oxygen atom or a single bond.

Abstract: A trifunctional (meth)acrylate compound represented by the following general formula (I); and a polymerizable composition containing the compound. The compound preferably is a compound in which ring A1, ring A2, and ring A3 in general formula (I) each is a benzene ring or naphthalene ring and at least one of the ring A1, ring A2, and ring A3 is a naphthalene ring, or is a compound in which X1, X2, and X3 each is —COO— or —OCO—. More preferred is a compound in which ring A3 is a naphthalene ring. Even more preferred is the compound which by itself can retain a liquid-crystal phase at 30° C. and lower temperatures. (In the formula, M1, M2, and M3 each represents methyl, etc.; rings A1, A2, and A3 each represents a benzene ring, naphthalene ring, etc.; Z1, Z2, and Z3 each represents C1-6 alkyl, etc.; X1, X2, and X3 each represents —COO—, —OCO—, etc.; Y1 and Y2 each represents -L1-, and Y3 represents -L2-, etc.

Abstract: A compound represented by the formula (1) is provided. A polymerizable liquid crystal composition containing the compound can be controlled in birefringence and is excellent in stability of a liquid crystal phase. An anisotropic polymer excellent in uniformity of alignment is obtained by coating and polymerizing the composition on a supporting substrate. In the formula (1), at least one of Ra represents a polymerizable group, A represents a ring group, Y and Z each represent a single bond or alkylene; in which —CH2— in the alkylene may be replaced by another group, and m and n each represent an integer of from 0 to 5.

Abstract: The invention relates to novel mesogenic dimeric compounds which are especially suitable for use in birefringent films with negative optical dispersion, to novel liquid crystal (LC) formulations and polymer films comprising them, and to the use of the dimers, formulations and films in optical, electrooptical, electronic, semiconducting or luminescent components or devices.

Abstract: The invention relates to novel calamitic mesogenic compounds which are especially suitable for use in birefringent films with negative optical dispersion, to novel liquid crystal (LC) formulations and polymer films comprising them, and to the use of the compounds, formulations and films in optical, electrooptical, electronic, semiconducting or luminescent components or devices.

Abstract: A photosensitive compound as a molecular resist whose size is smaller than conventional polymer for photoresist, and which can form a nano assembly, and a photoresist composition including the same are disclosed. The photosensitive compound represented by the following formula. Also, the present invention provides a photoresist composition comprising 1 to 85 wt % (weight %) of the photosensitive compound; 0.05 to 15 weight parts of a photo-acid generator with respect to 100 weight parts of the photosensitive compound; and 50 to 5000 weight parts of an organic solvent with respect to 100 weight parts of the photosensitive compound. In the formula, n is the number of repetition of an isopropyl oxide (—CH(CH3)CH2O—) monomer, and is an integer of 1 to 40, and R is an alkyl group of 1 to 20 carbon atoms or a cycloalkyl group of 3 to 20 carbon atoms.

Abstract: An acid generator represented by the following formula (1) is provided: wherein X represents an alkylene group having 1 to 10 carbon atoms, —X1—O—X2—, or a heteroatom selected from the group consisting of nitrogen, sulfur and fluorine; X1 and X2 each independently represent an alkylene group having 1 to 10 carbon atoms; Y represents a cyclic hydrocarbon group having 5 to 30 carbon atoms and containing one or more aromatic rings, while one or more hydrogen atoms on the ring of the cyclic hydrocarbon group may be substituted by one or more members selected from the group consisting of —O—Y1, —CO—Y2, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a perfluoroalkyl group having 1 to 4 carbon atoms, a perfluoroalkoxy group having 1 to 4 carbon atoms, a hydroxyalkyl group having 1 to 6 carbon atoms, a halogen atom, a hydroxyl group and a cyano group; Y1 and Y2 each independently represent an alkyl group having 1 to 6 carbon atoms; n represents an integer of 0 or 5; and A+

Abstract: The invention relates to derivatives of dihydroxyphenylalanine, to their synthesis and to pharmaceutical compositions containing said derivatives of dihydroxyphenylalanine. Furthermore, the invention relates to the use of said derivatives of dihydroxyphenylalanine and said pharmaceutical compositions for the treatment and prophylaxis of movement disorders, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, hemiparkinson-hemiatrophy, parkinsonian syndrome, Lewy body disease, frontotemporal dementia, Lytico-Bodig disease (parkinsonism/dementia/amyotrophic lateral sclerosis), striatonigral degeneration, Shy-Drager syndrome, sporadic olivopontocerebellar degeneration, progressive atrophy of the globus pallidus, progressive supranuclear palsy, Hallervorden-Spatz disease, Huntington's disease, X-linked dystonia-parkinsonism (Lubag), mitochondrial cytopathy with striatal necrosis, neuroacanthocytosis, restless legs syndrome, Wilson's disease.

Abstract: Shape memory main-chain smectic-C elastomers are described, as are methods for their preparation and monomers used in such methods. The elastomers are prepared by hydrosilylation of a reaction mixture including a liquid crystalline diene, a crosslinking agent, and a bis(silyl hydride) compound. The elastomers exhibit shape-memory properties and spontaneously reversible shape changes. They are useful for fabrication of shape memory articles including, for example, implantable medical devices, contact lenses, reversible embossing media, and Fresnel lenses.

Abstract: To provide a liquid crystal composition having low viscosity in a wide temperature range and to provide a liquid crystal device excellent in response speed in the wide temperature range, a compound represented by the following general formula (1) or (2) is contained in the composition. In the general formulae (1) and (2), R1 and R2 are each independently selected from alkyl groups, alkoxy groups, F atom, Cl atom, OCF3, CF3, phenyl groups each having a substituent, and phenyl rings each connected with a bridging group and having a substituent.

Abstract: The present invention provides a compound which has cytokine production inhibitory activity and is useful for the treatment of diseases which is associated with cytokine. The compound is represented by the following general formula (I) [wherein A represents a cyclic group which may be substituted; the partial structure -DE- represents a group represented by —CH2CH2— or —CH?CH—; W represents a group represented by —CH2—, —CH2CH2—, —CH?CH— or —CH?; the partial structure >XY— represents a group represented by >CH—(CH2)n—, >C?CH—, >CH—CH2—CH(OH)—, >CH—CH2—C(?O)—, >CH—O— or >CH—O—CO—, provided that when W is —CH?, then XY— represents C—(CH2)p—; Z represents a divalent aliphatic hydrocarbon group; R1 and R2, which may be the same or different, each represents a hydrogen atom, or a hydroxyl, alkoxy or alkoxyalkoxy group; m is an integer of 0 or 1].

Abstract: The present invention relates to the use of certain resorcinol derivatives as skin lightening agents.

Abstract: An organic single-crystalline film useful as a functional film in various devices is produced by selecting a liquid crystal material having a good molecular alignment regularity, disposing the liquid crystal material between a pair of boundaries exerting a thickness regulating force and solidifying the liquid crystal material while imparting a molecular alignment order by phase transition from a liquid crystal phase. The liquid crystal material may preferably be a smectic liquid crystal material which provides a uniform molecular alignment inclusive of the direction of the molecular long axis in a smectic phase.

Abstract: The invention concerns novel bi-aromatic compounds having the formula: which are analogs of vitamin D, the process of preparing them, as well as their use in pharmaceutical compositions in human or veterinary medicine, particularly in dermatology, cancer treatment, treatment of auto-immune diseases, and in organ or tissue transplants. Cosmetic compositions and methods of use are also included.

Abstract: 3-amino-3-arylpropan-1-ol compounds corresponding to the formula I in which R1 to R5, A and X have the meanings according to claim 1, and their preparation and use as medicaments.

Abstract: In accordance with the present invention, there are provided normal modified forms of nonsteroidal anti-inflammatory drugs. Modified NSAIDs according to the invention provide a new class of anti-inflammatory agent which provide the therapeutic benefits of NSAIDs while causing a much lower incidence of side-effects then typically observed with such agents.